September 2020

Exploring Association of Hormonal Therapy on Breast Cancer Incidence
Evidence regarding the possible role of estrogen with or without progesterone on the incidence of breast cancer (BC) has been contradictory, with some studies demonstrating increased risk of disease and others showing a protective effect. In an attempt to further clarify treatment strategies, the Women’s Health Initiative (WHI), followed women who were taking these medications prospectively to determine the incidence of new cases of BC. Read more.


Safety and Genital Effects of Toremifene Compared With Tamoxifen
For women diagnosed with breast cancer (BC), endocrine options for treatment depend on menopausal status. In premenopausal women, choice of adjuvant endocrine therapy is often based on the patient’s risk of recurrence and involves the use of ovarian suppression plus endocrine therapy. Selective estrogen receptor modulators are the mainstay of adjuvant BC therapy in this population. Read more

Adjuvant Paclitaxel and Carboplatin in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of BC cases in the U.S. However, despite its lower prevalence, this disease has a more virulent and aggressive course. Adding to this burden, approximately 11% of TNBC patients manifest BRAC1/2 variants, resulting in a dysfunctional BRCA pathway. These variants are associated with abnormal DNA repair and genome-wide instability. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App